Interesting to me CUV actually had a $40 SP post Co-vid. YOY...

Interesting to me CUV actually had a $40 SP post Co-vid. YOY 2022-2023 showed pretty good growth- around 30-40 % growth on most financials. They didn't get the SP rewards like PME and PME seems to have avoided the biotech pull back over recent times. No question their growth is standout and their SP looks pretty well priced even with the results and outlook. Unfortunately for CUV, they fell off the wave and haven't really got any momentum outside EPP (in terms of financial growth). The first half was disappointing and this may well be the catalyst for the shorting. I'm expecting a better second half but not quite the growth back in 2022/23. I guess it's possible if sales in Canada, Israel and Sth America have increased. We may also have benefited for those coming off trials from competitors. Expect more expenses but the cash should still be increasing. We'll see but at these prices, I see disappointment priced in and zero value on any near term revenue from the adolescent EPP, VP, OTC's, Vitiligo or ACTH IMO. GLTA Yes the buy back is insipid!